Cardiac Power Output in Cardiogenic Shock Patients
Key facts
- Where
- Chicago, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- The University Of ChicagoChicago, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Chicago
- Trial code
- NCT05700617
- Record updated
- 6 August 2026
- Original description
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.Read full original descriptionShow less
Myocardial Reserve in Advanced Heart Failure Patients
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Inclusion: LVEF ≤ 40%; Referred for RHC for:; Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR; Accurate assessment of invasive hemodynamics due to worsening clinical status, OR; Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR; Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI; Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2; Age ≥ 18 years-old; Intent for admission based on RHC data.
Exclusion: Concurrent acute coronary syndrome; Severe, non-revascularized coronary artery disease; History of significant ventricular arrhythmia without an ICD; eGFR < 30 ml/min/1.73 m2; Age < 18 years-old.